No Data
No Data
No Data
No Data
No Data
Dongbao Biotech (300239.SZ): Net profit of 259.615 million yuan in the first quarter decreased 16.62% year-on-year
Gelonghui, April 23 | Dongbao Biotech (300239.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 242 million yuan, down 7.48% year on year; net profit attributable to shareholders of listed companies was 25.9615 million yuan, down 16.62% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 236.22,300 yuan, down 21.61% year on year; basic earnings per share were 0.0437 yuan.
Gelonghui FinanceApr 23 07:15 ET
Do Its Financials Have Any Role To Play In Driving Baotou Dongbao Bio-Tech Co.,Ltd's (SZSE:300239) Stock Up Recently?
Baotou Dongbao Bio-TechLtd's (SZSE:300239) stock is up by a considerable 33% over the past week. As most would know, fundamentals are what usually guide market price movements over the long-term, so
Simply Wall StFeb 28 18:01 ET
Dongbao Biotech (300239.SZ): The subsidiary Yiqing Biotech has once again been certified as a high-tech enterprise
Gelonghui, Feb. 20, | Dongbao Biotech (300239.SZ) announced that the company's holding subsidiary, Qingdao Yiqing Biotechnology Co., Ltd. (“Yiqing Biotech”), recently received the “High-tech Enterprise Certificate” jointly approved and issued by the Qingdao Municipal Bureau of Science and Technology, the Qingdao Municipal Finance Bureau, and the Qingdao Municipal Taxation Bureau of the State Administration of Taxation. Yiqing Biotech has once again passed the high-tech enterprise certification.
Gelonghui FinanceFeb 20 05:56 ET
Not Many Are Piling Into Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) Stock Yet As It Plummets 30%
The Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) share price has fared very poorly over the last month, falling by a substantial 30%. The drop over the last 30 days has capped off a tough year for
Simply Wall StFeb 2 18:43 ET
Dongbao Biotech (300239.SZ) once again passed the high-tech enterprise certification
Gelonghui, January 23丨Dongbao Biotech (300239.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly approved and issued by the Inner Mongolia Autonomous Region Science and Technology Department, the Inner Mongolia Autonomous Region Finance Department, and the Inner Mongolia Autonomous Region Taxation Bureau of the State Administration of Taxation. The company once again passed the high-tech enterprise certification.
Gelonghui FinanceJan 23 04:54 ET
Toho Biotech (300239.SZ): Main products gelatin, collagen, capsules and terminal series products, etc.
Glonghui December 18丨Dongbao Biotech (300239.SZ) said on the investor interactive platform that the company's main products include gelatin, collagen, capsules and terminal products, etc., which are widely used in food, pharmaceuticals, health products, beauty and other fields. The company's collagen series products are basic nutrition and health products, mainly targeting middle-aged and elderly markets, women's markets, bone health markets, and sub-health markets.
Gelonghui FinanceDec 18, 2023 06:55 ET
No Data
No Data